A detailed history of Thoroughbred Financial Services, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Thoroughbred Financial Services, LLC holds 20,990 shares of HALO stock, worth $1.47 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
20,990
Previous 21,140 0.71%
Holding current value
$1.47 Million
Previous $1.1 Million 40.04%
% of portfolio
0.09%
Previous 0.08%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

SELL
$52.92 - $78.28 $7,938 - $11,742
-150 Reduced 0.71%
20,990 $1.54 Million
Q2 2025

Aug 08, 2025

BUY
$47.91 - $70.14 $1.01 Million - $1.48 Million
21,140 New
21,140 $1.1 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $9.75B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Thoroughbred Financial Services, LLC Portfolio

Follow Thoroughbred Financial Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thoroughbred Financial Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Thoroughbred Financial Services, LLC with notifications on news.